Gates launches $1bn vaccine initiative to target emerging infectious diseases

Affiliations

Anne Gulland. BMJ. 2017.

. 2017 Jan 19:356:j330.

doi: 10.1136/bmj.j330.

No abstract available

Similar articles

The ProVac initiative and evolving decision support.
Sanderson CF. Sanderson CF. Vaccine. 2015 May 7;33 Suppl 1:A8-10. doi: 10.1016/j.vaccine.2014.12.049. Vaccine. 2015. PMID: 25919181 No abstract available.
Perspectives on expanding the evidence base to inform vaccine introduction: Program costing and cost-effectiveness analyses.
Andrus JK, Walker DG. Andrus JK, et al. Vaccine. 2015 May 7;33 Suppl 1:A2-3. doi: 10.1016/j.vaccine.2015.01.001. Vaccine. 2015. PMID: 25919161 No abstract available.
Foreword.
Etienne CF. Etienne CF. Vaccine. 2015 May 7;33 Suppl 1:A1. doi: 10.1016/j.vaccine.2015.02.001. Vaccine. 2015. PMID: 25919148 No abstract available.
Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020.
Gandhi G, Lydon P, Cornejo S, Brenzel L, Wrobel S, Chang H. Gandhi G, et al. Vaccine. 2013 Apr 18;31 Suppl 2:B137-48. doi: 10.1016/j.vaccine.2013.01.036. Vaccine. 2013. PMID: 23598475 Review.
Global perspectives on vaccine financing.
Berman S, Giffin RB. Berman S, et al. Expert Rev Vaccines. 2004 Oct;3(5):557-62. doi: 10.1586/14760584.3.5.557. Expert Rev Vaccines. 2004. PMID: 15485335 Review.